Citigroup Downgrades Prime Medicine to Neutral, Lowers Price Target to $1.5
Benzinga Newsdesk 1 year ago
NewsDowngradesPrice TargetAnalyst Ratings
Citigroup analyst Samantha Semenkow downgrades Prime Medicine (NASDAQ:PRME) from Buy to Neutral and lowers the price target from $10 to $1.5.
Citigroup analyst Samantha Semenkow downgrades Prime Medicine (NASDAQ:PRME) from Buy to Neutral and lowers the price target from $10 to $1.5.